메뉴 건너뛰기




Volumn 122, Issue 14, 2016, Pages 2242-2250

Clinical and molecular markers of long-term survival after oligometastasis-directed stereotactic body radiotherapy (SBRT)

Author keywords

biomarker; classifier; microRNA; oligometastases; stereotactic body radiotherapy

Indexed keywords

MICRORNA; MOLECULAR MARKER;

EID: 84977565190     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.30058     Document Type: Article
Times cited : (109)

References (40)
  • 2
    • 0031012884 scopus 로고    scopus 로고
    • Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases
    • Pastorino U, Buyse M, Friedel G, et al. Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. J Thorac Cardiovasc Surg. 1997;113:37–49.
    • (1997) J Thorac Cardiovasc Surg. , vol.113 , pp. 37-49
    • Pastorino, U.1    Buyse, M.2    Friedel, G.3
  • 3
    • 0031052731 scopus 로고    scopus 로고
    • Liver resection for colorectal metastases
    • Fong Y, Cohen AM, Fortner JG, et al. Liver resection for colorectal metastases. J Clin Oncol. 1997;15:938–946.
    • (1997) J Clin Oncol. , vol.15 , pp. 938-946
    • Fong, Y.1    Cohen, A.M.2    Fortner, J.G.3
  • 4
    • 70249110476 scopus 로고    scopus 로고
    • Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients
    • de Jong MC, Pulitano C, Ribero D, et al. Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Ann Surg. 2009;250:440–448.
    • (2009) Ann Surg. , vol.250 , pp. 440-448
    • de Jong, M.C.1    Pulitano, C.2    Ribero, D.3
  • 5
    • 68949209656 scopus 로고    scopus 로고
    • Liver resection for metastatic colorectal cancer in the presence of extrahepatic disease
    • Carpizo DR, D'Angelica M. Liver resection for metastatic colorectal cancer in the presence of extrahepatic disease. Ann Surg Oncol. 2009;16:2411–2421.
    • (2009) Ann Surg Oncol. , vol.16 , pp. 2411-2421
    • Carpizo, D.R.1    D'Angelica, M.2
  • 6
    • 84861581912 scopus 로고    scopus 로고
    • Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study
    • Milano MT, Katz AW, Zhang H, Okunieff P. Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. Int J Radiat Oncol Biol Phys. 2012;83:878–886.
    • (2012) Int J Radiat Oncol Biol Phys. , vol.83 , pp. 878-886
    • Milano, M.T.1    Katz, A.W.2    Zhang, H.3    Okunieff, P.4
  • 7
    • 67349257418 scopus 로고    scopus 로고
    • Oligometastatic breast cancer treated with curative-intent stereotactic body radiation therapy
    • Milano MT, Zhang H, Metcalfe SK, Muhs AG, Okunieff P. Oligometastatic breast cancer treated with curative-intent stereotactic body radiation therapy. Breast Cancer Res Treat. 2009;115:601–608.
    • (2009) Breast Cancer Res Treat. , vol.115 , pp. 601-608
    • Milano, M.T.1    Zhang, H.2    Metcalfe, S.K.3    Muhs, A.G.4    Okunieff, P.5
  • 8
    • 84937974394 scopus 로고    scopus 로고
    • Lung metastases in oligometastatic patients: outcome with stereotactic body radiation therapy (SBRT)
    • Garcia-Cabezas S, Bueno C, Rivin E, Roldan JM, Palacios-Eito A. Lung metastases in oligometastatic patients: outcome with stereotactic body radiation therapy (SBRT). Clin Transl Oncol. 2016;17:668–672.
    • (2016) Clin Transl Oncol. , vol.17 , pp. 668-672
    • Garcia-Cabezas, S.1    Bueno, C.2    Rivin, E.3    Roldan, J.M.4    Palacios-Eito, A.5
  • 9
    • 84912075430 scopus 로고    scopus 로고
    • Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients
    • Collen C, Christian N, Schallier D, et al. Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients. Ann Oncol. 2014;25:1954–1959.
    • (2014) Ann Oncol. , vol.25 , pp. 1954-1959
    • Collen, C.1    Christian, N.2    Schallier, D.3
  • 10
    • 84863716833 scopus 로고    scopus 로고
    • High dose stereotactic body radiotherapy using 3 fractions for colorectal oligometastases
    • Bae SH, Kim MS, Cho CK, et al. High dose stereotactic body radiotherapy using 3 fractions for colorectal oligometastases. J Surg Oncol. 2012;106:138–143.
    • (2012) J Surg Oncol. , vol.106 , pp. 138-143
    • Bae, S.H.1    Kim, M.S.2    Cho, C.K.3
  • 11
    • 63749100778 scopus 로고    scopus 로고
    • Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases
    • Rusthoven KE, Kavanagh BD, Burri SH, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol. 2009;27:1579–1584.
    • (2009) J Clin Oncol. , vol.27 , pp. 1579-1584
    • Rusthoven, K.E.1    Kavanagh, B.D.2    Burri, S.H.3
  • 12
    • 63749100778 scopus 로고    scopus 로고
    • Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases
    • Rusthoven KE, Kavanagh BD, Cardenes H, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol. 2009;27:1572–1578.
    • (2009) J Clin Oncol. , vol.27 , pp. 1572-1578
    • Rusthoven, K.E.1    Kavanagh, B.D.2    Cardenes, H.3
  • 13
    • 84926222348 scopus 로고    scopus 로고
    • Survival and prognostic factors in 321 patients treated with stereotactic body radiotherapy for oligo-metastases
    • Fode MM, Hoyer M. Survival and prognostic factors in 321 patients treated with stereotactic body radiotherapy for oligo-metastases. Radiother Oncol. 2015;114:155–160.
    • (2015) Radiother Oncol. , vol.114 , pp. 155-160
    • Fode, M.M.1    Hoyer, M.2
  • 14
    • 84991987379 scopus 로고    scopus 로고
    • Surgery or ablative radiotherapy for breast cancer oligometastases
    • Salama JK, Chmura SJ. Surgery or ablative radiotherapy for breast cancer oligometastases. Am Soc Clin Oncol Educ Book. 2015;35:e8–e15.
    • (2015) Am Soc Clin Oncol Educ Book. , vol.35 , pp. e8-e15
    • Salama, J.K.1    Chmura, S.J.2
  • 15
    • 84861334635 scopus 로고    scopus 로고
    • Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease
    • Salama JK, Hasselle MD, Chmura SJ, et al. Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. Cancer. 2012;118:2962–2970.
    • (2012) Cancer. , vol.118 , pp. 2962-2970
    • Salama, J.K.1    Hasselle, M.D.2    Chmura, S.J.3
  • 16
    • 10744228140 scopus 로고    scopus 로고
    • CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment
    • Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13:176–181.
    • (2003) Semin Radiat Oncol. , vol.13 , pp. 176-181
    • Trotti, A.1    Colevas, A.D.2    Setser, A.3
  • 17
    • 0028969271 scopus 로고
    • Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)
    • Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31:1341–1346.
    • (1995) Int J Radiat Oncol Biol Phys. , vol.31 , pp. 1341-1346
    • Cox, J.D.1    Stetz, J.2    Pajak, T.F.3
  • 18
    • 83255163997 scopus 로고    scopus 로고
    • MicroRNA expression characterizes oligometastasis(es)
    • Lussier YA, Xing HR, Salama JK, et al. MicroRNA expression characterizes oligometastasis(es). PLoS One. 2011;6:e28650.
    • (2011) PLoS One. , vol.6
    • Lussier, Y.A.1    Xing, H.R.2    Salama, J.K.3
  • 20
    • 84926507971 scopus 로고    scopus 로고
    • limma powers differential expression analyses for RNA-sequencing and microarray studies [serial online]
    • Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies [serial online]. Nucleic Acids Res. 2015;43:e47.
    • (2015) Nucleic Acids Res. , vol.43
    • Ritchie, M.E.1    Phipson, B.2    Wu, D.3
  • 21
    • 0001677717 scopus 로고
    • Controlling the false discovery rate: a practical and powerful approach to multiple testing
    • Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B. 1995;57:289–300.
    • (1995) J R Stat Soc B. , vol.57 , pp. 289-300
    • Benjamini, Y.1    Hochberg, Y.2
  • 22
    • 77950537175 scopus 로고    scopus 로고
    • Regularization paths for generalized linear models via coordinate descent
    • Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. J Stat Softw. 2010;33:1–22.
    • (2010) J Stat Softw. , vol.33 , pp. 1-22
    • Friedman, J.1    Hastie, T.2    Tibshirani, R.3
  • 23
    • 77955157844 scopus 로고    scopus 로고
    • JM: an R package for the joint modelling of longitudinal and time-to-event data
    • Rizopoulos D. JM: an R package for the joint modelling of longitudinal and time-to-event data. J Stat Soft. 2010;35:1–33.
    • (2010) J Stat Soft. , vol.35 , pp. 1-33
    • Rizopoulos, D.1
  • 25
    • 84893379567 scopus 로고    scopus 로고
    • Stereotactic radiotherapy for oligometastatic cancer: a prognostic model for survival
    • de Vin T, Engels B, Gevaert T, Storme G, De Ridder M. Stereotactic radiotherapy for oligometastatic cancer: a prognostic model for survival. Ann Oncol. 2014;25:467–471.
    • (2014) Ann Oncol. , vol.25 , pp. 467-471
    • de Vin, T.1    Engels, B.2    Gevaert, T.3    Storme, G.4    De Ridder, M.5
  • 26
    • 84907011125 scopus 로고    scopus 로고
    • Radical irradiation of extracranial oligometastases
    • Salama JK, Milano MT. Radical irradiation of extracranial oligometastases. J Clin Oncol. 2014;32:2902–2912.
    • (2014) J Clin Oncol. , vol.32 , pp. 2902-2912
    • Salama, J.K.1    Milano, M.T.2
  • 27
    • 84909581571 scopus 로고    scopus 로고
    • The oligometastatic state-separating truth from wishful thinking
    • Palma DA, Salama JK, Lo SS, et al. The oligometastatic state-separating truth from wishful thinking. Nat Rev Clin Oncol. 2014;11:549–557.
    • (2014) Nat Rev Clin Oncol. , vol.11 , pp. 549-557
    • Palma, D.A.1    Salama, J.K.2    Lo, S.S.3
  • 28
    • 84870945783 scopus 로고    scopus 로고
    • Oligo- and polymetastatic progression in lung metastasis(es) patients is associated with specific microRNAs [serial online]
    • Lussier YA, Khodarev NN, Regan K, et al. Oligo- and polymetastatic progression in lung metastasis(es) patients is associated with specific microRNAs [serial online]. PLoS One. 2012;7:e50141.
    • (2012) PLoS One. , vol.7
    • Lussier, Y.A.1    Khodarev, N.N.2    Regan, K.3
  • 29
    • 84924251051 scopus 로고    scopus 로고
    • 14q32-Encoded microRNAs mediate an oligometastatic phenotype
    • Uppal A, Wightman SC, Mallon S, et al. 14q32-Encoded microRNAs mediate an oligometastatic phenotype. Oncotarget. 2015;6:3540–3552.
    • (2015) Oncotarget. , vol.6 , pp. 3540-3552
    • Uppal, A.1    Wightman, S.C.2    Mallon, S.3
  • 30
    • 82555193281 scopus 로고    scopus 로고
    • Genome-wide functional screening of miR-23b as a pleiotropic modulator suppressing cancer metastasis [serial online]
    • Zhang H, Hao Y, Yang J, et al. Genome-wide functional screening of miR-23b as a pleiotropic modulator suppressing cancer metastasis [serial online]. Nat Commun. 2011;2:554.
    • (2011) Nat Commun. , vol.2 , pp. 554
    • Zhang, H.1    Hao, Y.2    Yang, J.3
  • 31
    • 84899647898 scopus 로고    scopus 로고
    • MicroRNA-23b is an independent prognostic marker and suppresses ovarian cancer progression by targeting runt-related transcription factor-2
    • Li W, Liu Z, Chen L, Zhou L, Yao Y. MicroRNA-23b is an independent prognostic marker and suppresses ovarian cancer progression by targeting runt-related transcription factor-2. FEBS Lett. 2014;588:1608–1615.
    • (2014) FEBS Lett. , vol.588 , pp. 1608-1615
    • Li, W.1    Liu, Z.2    Chen, L.3    Zhou, L.4    Yao, Y.5
  • 32
    • 84871222985 scopus 로고    scopus 로고
    • miR-23b represses proto-oncogene Src kinase and functions as methylation-silenced tumor suppressor with diagnostic and prognostic significance in prostate cancer
    • Majid S, Dar AA, Saini S, et al. miR-23b represses proto-oncogene Src kinase and functions as methylation-silenced tumor suppressor with diagnostic and prognostic significance in prostate cancer. Cancer Res. 2012;72:6435–6446.
    • (2012) Cancer Res. , vol.72 , pp. 6435-6446
    • Majid, S.1    Dar, A.A.2    Saini, S.3
  • 33
    • 84870021606 scopus 로고    scopus 로고
    • Inhibition of PTEN gene expression by oncogenic miR-23b-3p in renal cancer [serial online]
    • Zaman MS, Thamminana S, Shahryari V, et al. Inhibition of PTEN gene expression by oncogenic miR-23b-3p in renal cancer [serial online]. PLoS One. 2012;7:e50203.
    • (2012) PLoS One. , vol.7
    • Zaman, M.S.1    Thamminana, S.2    Shahryari, V.3
  • 34
    • 84877766516 scopus 로고    scopus 로고
    • Prooncogenic factors miR-23b and miR-27b are regulated by Her2/Neu, EGF, and TNF-alpha in breast cancer
    • Jin L, Wessely O, Marcusson EG, Ivan C, Calin GA, Alahari SK. Prooncogenic factors miR-23b and miR-27b are regulated by Her2/Neu, EGF, and TNF-alpha in breast cancer. Cancer Res. 2013;73:2884–2896.
    • (2013) Cancer Res. , vol.73 , pp. 2884-2896
    • Jin, L.1    Wessely, O.2    Marcusson, E.G.3    Ivan, C.4    Calin, G.A.5    Alahari, S.K.6
  • 35
    • 79952706449 scopus 로고    scopus 로고
    • miR-449 inhibits cell proliferation and is down-regulated in gastric cancer [serial online]
    • Bou Kheir T, Futoma-Kazmierczak E, Jacobsen A, et al. miR-449 inhibits cell proliferation and is down-regulated in gastric cancer [serial online]. Mol Cancer. 2011;10:29.
    • (2011) Mol Cancer. , vol.10 , pp. 29
    • Bou Kheir, T.1    Futoma-Kazmierczak, E.2    Jacobsen, A.3
  • 36
    • 84944879420 scopus 로고    scopus 로고
    • MiR-449a suppresses the epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma by multiple targets [serial online]
    • Chen SP, Liu BX, Xu J, et al. MiR-449a suppresses the epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma by multiple targets [serial online]. BMC Cancer. 2015;15:706.
    • (2015) BMC Cancer. , vol.15 , pp. 706
    • Chen, S.P.1    Liu, B.X.2    Xu, J.3
  • 37
    • 70350111289 scopus 로고    scopus 로고
    • miR-449a and miR-449b are direct transcriptional targets of E2F1 and negatively regulate pRb-E2F1 activity through a feedback loop by targeting CDK6 and CDC25A
    • Yang X, Feng M, Jiang X, et al. miR-449a and miR-449b are direct transcriptional targets of E2F1 and negatively regulate pRb-E2F1 activity through a feedback loop by targeting CDK6 and CDC25A. Genes Dev. 2009;23:2388–2393.
    • (2009) Genes Dev. , vol.23 , pp. 2388-2393
    • Yang, X.1    Feng, M.2    Jiang, X.3
  • 38
    • 64949190804 scopus 로고    scopus 로고
    • miR-449a targets HDAC-1 and induces growth arrest in prostate cancer
    • Noonan EJ, Place RF, Pookot D, et al. miR-449a targets HDAC-1 and induces growth arrest in prostate cancer. Oncogene. 2009;28:1714–1724.
    • (2009) Oncogene. , vol.28 , pp. 1714-1724
    • Noonan, E.J.1    Place, R.F.2    Pookot, D.3
  • 39
    • 84924408128 scopus 로고    scopus 로고
    • High miR-449b expression in prostate cancer is associated with biochemical recurrence after radical prostatectomy
    • Mortensen MM, Hoyer S, Orntoft TF, Sorensen KD, Dyrskjot L, Borre M. High miR-449b expression in prostate cancer is associated with biochemical recurrence after radical prostatectomy. BMC Cancer. 2014;14:859.
    • (2014) BMC Cancer. , vol.14 , pp. 859
    • Mortensen, M.M.1    Hoyer, S.2    Orntoft, T.F.3    Sorensen, K.D.4    Dyrskjot, L.5    Borre, M.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.